Mesenchymal stem cell-derived apoptotic vesicles regulate irritable bowel syndrome in mice via the 5-HT brain-gut axis.
Sun Y., Wu D., Lu L., Wang J., Li X., Mao X.
Prospective Study, published in Stem Cell Res Ther (2025) — summary generated from the PubMed abstract.
Early human evidence such as case series or small samples is exploring possible benefits.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Prospective Study
- Journal
- Stem Cell Res Ther (2025)
- Country
- England
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 40598603
- PMCID
- PMC12210603
- DOI
- 10.1186/s13287-025-04448-6
- Citations
- 3
Abstract (original English)
Background Irritable Bowel Syndrome (IBS) is a common functional gastrointestinal disorder characterized by abnormal brain-gut interactions. The pathogenic mechanisms of IBS are not fully understood, and current treatments are limited in efficacy. Aims This study aims to investigate the potential therapeutic effects of mesenchymal stem cell-derived apoptotic vesicles (apoVs) on IBS in a mouse model, focusing on their impact on the 5-HT brain-gut axis. Methods We extracted and characterized apoVs from adipose-derived stem cells (ADSCs, Mesenchymal stem cells derived from adipose) induced to undergo apoptosis. IBS was induced in C57BL/6 mice using a chronic stress model. Mice were treated with apoVs via tail vein injection, and various behavioral, physiological, and biochemical parameters were assessed. Results IBS patients exhibited increased circulating vesicles in peripheral blood, correlating with brain functional activity. Further animal studies found that apoVs treatment in IBS mice reduced 5-HT levels in the brain and gut, alleviated symptoms such as slowed weight gain and visceral hypersensitivity, and restored intestinal barrier function. Additionally, apoVs improved neuronal activation and mucin secretion in the gut. Conclusions Our findings suggest that apoVs act as novel messengers in brain-gut axis interactions, regulating brain-gut homeostasis. This study provides a
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
Evidence level
Early human evidence such as case series or small samples is exploring possible benefits.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.